MARKET

GLMD

GLMD

Galmed Pharmaceu
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5103
-0.0151
-2.87%
After Hours: 0.5104 +0.0001 +0.02% 19:55 05/27 EDT
OPEN
0.5254
PREV CLOSE
0.5254
HIGH
0.5310
LOW
0.5100
VOLUME
279.79K
TURNOVER
0
52 WEEK HIGH
4.080
52 WEEK LOW
0.5000
MARKET CAP
12.80M
P/E (TTM)
-0.3865
1D
5D
1M
3M
1Y
5Y
Galmed Pharmaceuticals shares fall after downgrade by Raymond James analyst
Galmed Pharmaceuticals (NASDAQ:GLMD) shares fell 8.41% after Raymond James Analyst Steven Seedhouse downgraded the ratings of the biotechnology company to Market Perform from Outperform without a price target. The company
Seekingalpha · 05/18 15:05
Galmed Pharmaceuticals Shares Fall After Rating Downgrade From Raymond James
MT Newswires · 05/18 12:30
--Raymond James Downgrades Galmed Pharmaceuticals to Market Perform From Outperform
MT Newswires · 05/18 05:47
Galmed GAAP EPS of -$0.24 beats by $0.08
Galmed press release (NASDAQ:GLMD): Q1 GAAP EPS of -$0.24 beats by $0.08. Cash and cash equivalents, restricted cash and marketable debt securities totaled $28.9 million as of March 31,2022, compared
Seekingalpha · 05/17 12:50
Galmed Pharmaceuticals: Q1 Earnings Insights
  Galmed Pharmaceuticals (NASDAQ:GLMD) reported its Q1 earnings results on Tuesday, May 17, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 05/17 12:25
Galmed Pharmaceuticals Q1 EPS $(0.24) Beats $(0.32) Estimate
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.32) by 25 percent. This is a 36.84 percent increase over losses of $(0.38) per share
Benzinga · 05/17 12:10
BRIEF-Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
reuters.com · 05/17 12:04
BRIEF-Galmed Updates Business And Clinical Development Strategy To Better Leverage Aramchol's Anti-Fibrotic Effects
reuters.com · 05/17 11:43
More
No Data
Learn about the latest financial forecast of GLMD. Analyze the recent business situations of Galmed Pharmaceu through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
60.00%Buy
20.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GLMD stock price target is 4.500 with a high estimate of 5.00 and a low estimate of 3.000.
High5.00
Average4.500
Low3.000
Current 0.5103
EPS
Actual
Estimate
-0.30-0.23-0.15-0.08
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 35
Institutional Holdings: 3.97M
% Owned: 15.83%
Shares Outstanding: 25.09M
TypeInstitutionsShares
Increased
2
43.36K
New
4
40.10K
Decreased
4
84.90K
Sold Out
5
1.06M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
President/Chief Executive Officer/Director
Allen Baharaff
Chief Financial Officer
Doron Cohen
Chief Operating Officer
Guy Nehemya
Chief Accounting Officer
Yohai Stenzler
Chief Scientific Officer
Liat Hayardeny
Lead Director/Independent Director
David Sidransky
Independent Director
Carol Brosgart
Independent Director
Marshall Heinberg
Independent Director
Shmuel Nir
Independent Director
Amir Poshinski
No Data
No Data
About GLMD
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

Webull offers kinds of Galmed Pharmaceuticals Ltd stock information, including NASDAQ:GLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLMD stock methods without spending real money on the virtual paper trading platform.